Research-only: Mito / Fatigue / Readiness (SS-31 + MOTS-C)

Public • 2/6/2026

Mitochondria-oriented peptide grouping. SS-31 has clinical trials in specific mitochondrial diseases; MOTS-C is mostly preclinical.

← Back Buy stack

Practical pre-check

Deterministic heuristics (stimulants, duplicates, hydration). Not medical advice.

Supplements

Items in this stack

Training load

Unknown load

Need more wearable data

Stimulant estimate

0 mg

Only counts explicit caffeine items

Looks clean

No obvious duplication/stimulant/hydration flags from the heuristic pass.

AI risk assessment

Context: No wearable data

No assessment yet.

Supplements

2 items

SS-31 (Elamipretide)Moderate

PLACEHOLDER • Lyophilized • Click to expand

Clinical data exists in mitochondrial myopathy (endpoint-dependent).

Buy ingredient →

1mg

Efficacy and safety — phase 3 primary endpoints not met

Moderate

Population: Adults with primary mitochondrial myopathy (n=218)

Study type: Randomized, double-blind, placebo-controlled phase 3 trial (MMPOWER-3)

Dose context: — • Duration: 24 weeks

MMPOWER-3 found no significant improvement in 6-minute walk test distance or fatigue scores with 40 mg/day subcutaneous elamipretide vs. placebo over 24 weeks in the overall PMM population (Class I evidence of no benefit on primary endpoints). A post-hoc subgroup analysis suggested possible benefit in patients with nuclear DNA variants. Elamipretide was well-tolerated.

Citation: Karaa et al., Neurology (2023) — MMPOWER-3 Randomized Clinical Trial•https://pubmed.ncbi.nlm.nih.gov/37268435/

Exercise performance (short-term, earlier phase 2 dose-escalation)

Moderate

Population: Adults with primary mitochondrial myopathy

Study type: Randomized dose-escalation clinical trial

Dose context: — • Duration: 5 days

An earlier short-course dose-escalation study reported improved exercise performance after 5 days; the larger phase 3 MMPOWER-3 trial did not confirm sustained benefit on primary endpoints.

Citation: Karaa et al., Neurology (2018) — randomized dose-escalation elamipretide in PMM•DOI: 10.1212/WNL.0000000000005255•https://pmc.ncbi.nlm.nih.gov/articles/PMC5890606/

MOTS-CLow

PLACEHOLDER • Other • Click to expand

Mostly preclinical metabolic/exercise signaling; limited established human efficacy evidence.

Buy ingredient →

1mg

Running performance under metabolic stress

Low

Population: Mice on high-fat diet (preclinical)

Study type: Animal study

Dose context: — • Duration: Preclinical protocol (see paper)

In mice, MOTS-c treatment improved treadmill running performance under diet-induced metabolic stress and showed metabolic regulatory effects.

Citation: Reynolds et al., Nat Commun (2021) — exercise-induced MOTS-c biology and performance in mice•DOI: 10.1038/s41467-020-20790-0•https://www.nature.com/articles/s41467-020-20790-0

Clinical translation status

Low

Population: Humans (clinical development commentary)

Study type: Review / perspective

Dose context: —

Reviews note that clinical trials to test therapeutic MOTS-c potential are limited/ongoing; overall human efficacy evidence remains early. Blood MOTS-c levels are reported lower in type 2 diabetes and obesity, but therapeutic dosing in humans has not been validated.

Citation: Lee et al., Diabetes Metab J (2023) — MOTS-c, diabetes, and related clinical perspective•https://pmc.ncbi.nlm.nih.gov/articles/PMC9905433/

Exercise/metabolic signaling (summary)

Very low

Population: Mostly preclinical

Study type: Review

Dose context: —

Reviews propose metabolic and stress-response roles primarily based on preclinical evidence; no effective method of applying MOTS-c in the clinic has been established as of 2024-2025.

Citation: Ming et al., Front Endocrinol (2023) — MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation•https://pmc.ncbi.nlm.nih.gov/articles/PMC9905433/